New Data from Carisma Therapeutics Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

May 15, 2020

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, shares details from new data findings accepted for presentation at leading healthcare conferences, the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and the American Association for Cancer Research (AACR) Annual Meeting. Accepted data build on foundational, preclinical findings in Nature Biotechnology’s “Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy,” first published in March 2020. Additionally, new studies led by Carisma Therapeutics’ Drug Discovery team investigate the use of anti-HER2 CAR monocytes (CAR-Mono) to potentially expedite the manufacturing process, resulting in a shorter isolation-to-infusion time for immunotherapies.

In addition to the growing body of evidence supporting the CAR-M platform, Carisma Therapeutics researchers, in collaboration with the University of Pennsylvania Abramson Cancer Center, are also exploring the feasibility of a CAR-Monocyte platform.

Full press release here